Nuclear Pharm-Assist device for patients seeking care for cardiac, cancer diseases

Positron Corporation (OTCBB:POSC) is a molecular imaging solutions company focused on Nuclear Cardiology states that its proprietary product line also includes unique solutions for the oncology community designed to enhance its position in this industry.

“While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors.”

The Company's Nuclear Pharm-Assist®, an automated radiopharmaceutical dose dispensing device aims to greatly transform the way healthcare providers serve patients seeking care for numerous cardiac and cancer diseases.

The innovative device has been attracting significant new partners by streamlining the production, dispensing and delivery of radiopharmaceuticals.

"We believe Positron's dose dispensing device will revolutionize the way radiopharmaceuticals are compounded and distributed in the US and around the world. Positron's products, services and position in the marketplace provide an economical, efficient and regulatory compliant solution in the multibillion dollar per year radiopharmaceutical consumables industry," said Positron's CEO Patrick G. Rooney. "While most in the industry already know that PET is the future of nuclear cardiology, we fully expect that an equal to greater amount of revenue and profits will be generated by our new proprietary automated radiopharmaceutical device as it is used in both the cardiac and oncology sectors."

Through automation procedures which are normally manually performed by technologists, pharmacists and staff, Positron's platform is able to expedite and deliver difficult to handle and transport doses at medical treatment facilities of all sizes. At the same time, the Nuclear Pharm-Assist®, meets the strictest guidelines for radiation exposure and is designed as a platform for compliance with United States Pharmacopeia regulations (USP 797).

Next week, the Company is scheduled to address investors and discuss Positron and the nuclear medicine industry's demand for its products and how current and future opportunities will significantly impact the industry and the Company.

Positron Corporation's Press Conference

When: May 5, 2010, 1:00 pm EDT

Where: NASDAQ MarketSite, 4 Times Square, New York, NY